Drug intelligence / Profile preview

cm-182

Development stage: Unknown
Lead developer: Curemark
Modality: Small Molecules

Overview

CM-182 is a novel compound developed by Curemark for the treatment of neurological diseases, with a primary focus on schizophrenia and hyperactivity. The mechanism of action is currently undefined. Preclinical studies in mouse models have shown that CM-182 reduces hyperactivity without sedating effects, suggesting potential advantages over existing treatments for these conditions[1][3][4]. The drug has reached Phase 1 clinical development for schizophrenia[2].

Beyond the preview

Go deeper on cm-182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cm-182.

Explore the full profile